SBL-3 Multifocal Intraocular Lens
Lenstec, Inc. · Decision date Jul 22, 2022
What did the FDA approve?
FDA records P200020 as an original PMA application. The recorded decision is approval, dated Jul 22, 2022.
FDA approval order statement
Approval for the Lenstec SBL-3 Multifocal Intraocular Lens. This Lenstec SBL-3 Multifocal Intraocular Lens is indicated for primary implantation for the visual correction of aphakia, in adult patients with 1 diopter or less of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing a bifocal correction. Compared to an aspheric monofocal IOL, the lens provides improved near visual acuity, while maintaining comparable distance and intermediate visual acuity. The lens promotes the less frequent use of vision correction choices at near distance (including glasses, contact lenses, magnifying glasses, and digital adjustments on electronic devices), compared to an aspheric monofocal IOL, as reported in patient-reported outcomes. The SBL-3 multifocal IOL is intended for capsular bag placement only.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Jul 22, 2022
Regulatory record facts
- Identifier
- P200020
- Regulatory pathway
- Premarket approval application
- Applicant
- Lenstec, Inc.
- Product code
- MFK
- Decision code
- APPR
- Decision date
- Jul 22, 2022
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Applicant
- Lenstec, Inc.
- Product code
- MFK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200020 received
Application receipt date recorded by FDA.
P200020 · FDA decision
APPR
P200020/S013 · Related supplement
ClearView HD intraocular lens (IOL)
Timeline entries are records held by MedtechLedger for P200020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA | |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lenstec, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1765 Commerce Ave. N, St. Petersburg, FL, 33716
Sources and methodology
- Original FDA record: P200020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



